Stay updated on Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.1 to v3.7.2 while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-15T20:59:53.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-08T21:35:44.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the study details with an access-denied notice. The error screen includes the standard site chrome and footer, indicating the content is not reachable in this view.
    Difference
    24%
    Check dated 2026-09-24T20:41:52.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The page revision label has been updated from v3.6.6 to v3.7.0, indicating a new revision of the page rather than a substantive change to the study details.
    Difference
    0.0%
    Check dated 2026-09-17T21:57:16.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    Enrollment updated to 89 participants, and key dates updated from estimated to actual: primary completion on 2026-06-10 and study completion on 2027-08-26, with the latest update posted on 2026-08-28.
    Difference
    0.3%
    Check dated 2026-09-03T19:55:59.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    UPMC Hillman Cancer Center was added as a Pittsburgh study site, and University of Pittsburgh Cancer Institute (UPCI) was removed from the listed locations.
    Difference
    0.1%
    Check dated 2026-08-06T16:39:51.000Z thumbnail image

Stay in the know with updates to Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial page.